Viking's monthly obesity injection shows weight maintenance after switch
Viking Therapeutics presented data indicating that patients who moved to a once-monthly dosing of its obesity drug maintained their weight loss over 12 weeks. The results support the feasibility of a less frequent administration schedule for the treatment.
This development marks a notable step in the ongoing effort to make obesity treatments more convenient and sustainable for patients. Current therapies often require frequent injections, which can be a barrier to adherence and long-term success. The data suggesting that a monthly dose can preserve weight loss after an initial period points toward a potential shift in how such medications are administered. While the findings are preliminary and limited to a 12-week observation, they add to a broader trend in drug development aimed at reducing dosing frequency without sacrificing efficacy. Further studies would be needed to confirm durability and safety over longer intervals.
If confirmed, a monthly obesity injection could ease the burden on patients who struggle with weekly regimens, potentially improving adherence and long-term health outcomes. This may also reduce healthcare visits and associated costs, benefiting both individuals and systems. However, access and affordability remain key questions, as newer obesity drugs are often expensive. The impact would depend on pricing, insurance coverage, and whether the maintenance effect holds in larger, longer trials.